5 Key Takeaways
-
1
The port delivery system for neovascular age-related macular degeneration maintains vision for 5 to 7 years with minimal dropoff.
-
2
Eighty-five percent of patients using the port delivery system show no intraretinal fluid over the study period.
-
3
The incidence of endophthalmitis with the port delivery system is 2.8% over 8 years, comparable to the cumulative risk of multiple injections.
-
4
In the diabetic macular edema trial, the incidence of endophthalmitis with the port delivery system decreased to 1.1%.
-
5
Refill intervals for the port delivery system can vary, with some clinicians opting for every 6 months, while others extend to 9 months or longer.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.